Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG

Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd., Atlanta, GA 30333, USA.
Journal of immunological methods (Impact Factor: 1.82). 12/2011; 376(1-2):97-107. DOI: 10.1016/j.jim.2011.12.002
Source: PubMed


Accurate, reliable and standardized quantification of anti-protective antigen (PA) IgG antibody levels is essential for comparative analyses of anti-toxin immune responses in anthrax cases, recipients of PA-based anthrax vaccines and for evaluation of anti-PA based immunotherapies. We have previously reported the early performance characteristics and application of a quantitative anti-PA IgG enzyme linked immunosorbent assay. The principal application of this assay was in a Phase 4 human clinical trial of anthrax vaccine adsorbed (AVA, BioThrax), the central component of the CDC Anthrax Vaccine Research Program (AVRP) and in humans following bioterrorism associated Bacillus anthracis infection (Quinn et al., 2002; Quinn et al., 2004; Marano et al., 2008). The objective of the AVRP was to determine the feasibility of reducing the number of priming series and booster doses of the licensed Anthrax Vaccine Adsorbed (AVA) (BioThrax®; Emergent BioSolutions, Lansing, MI) and changing the route of administration from subcutaneous (SC) to intramuscular (IM) (Marano et al., 2008). In this paper we report the validation and long term performance characteristics of the assay during its six year application in the AVRP (2002-2008). The critical features are 1) extensive validation of the assay using two standard reference sera; 2) long term stability and 3) consistency of the data for quantitative analysis of human long term anti-PA IgG responses. The reportable value (RV) of the assay was expressed as anti-PA IgG concentration (μg/ml). Accuracy of the assay was high with a percent error (%ER) range of 1.6-11.4%. Overall intra-operator and intermediate precision were high with Coefficients of Variation (%CVs) of 2.5-15.4% and 6.3-13.2%, respectively. The assay demonstrated excellent dilutional linearity for human sera using log(10) transformed data with the slope=0.95 to 0.99, intercept=0.02 to 0.06 and r(2)=0.980-0.987. The assay was robust, tolerating changes in serum incubation temperatures from 35 to 39°C, serum incubation times from 55 to 65min and changes in key reagents. The long-term assay stability over 6years using consecutive reference sera AVR414 and AVR801 demonstrated sustained high accuracy and precision for the assay, confirming its suitability for long term studies of PA protein-based anthrax vaccines.

Download full-text


Available from: Conrad P Quinn, Mar 03, 2015
  • Source
    • "were then used as the initial serum dilution following the standard serum anti-PA IgG ELISA assay procedure [3]. Fig. 1 "
    [Show abstract] [Hide abstract]
    ABSTRACT: The collection, processing and transportation to a testing laboratory of large numbers of clinical samples during an emergency response situation present significant cost and logistical issues. Blood and serum are common clinical samples for diagnosis of disease. Serum preparation requires significant on-site equipment and facilities for immediate processing and cold storage, and significant costs for cold-chain transport to testing facilities. The dried blood spot (DBS) matrix offers an alternative to serum for rapid and efficient sample collection with fewer on-site equipment requirements and considerably lower storage and transport costs. We have developed and validated assay methods for using DBS in the quantitative anti-protective antigen IgG enzyme-linked immunosorbent assay (ELISA), one of the primary assays for assessing immunogenicity of anthrax vaccine and for confirmatory diagnosis of Bacillus anthracis infection in humans. We have also developed and validated high-throughput data analysis software to facilitate data handling for large clinical trials and emergency response.
    Full-text · Article · Dec 2012 · Biologicals
  • Source
    • "Methods for the measurement of AbPA using a quantitative enzyme-linked immunosorbent assay (ELISA) are described in Semenova et al. [16]. As in our previous analysis of HLA polymorphisms [8], we focus here on responses during the initial 7 months of the AVA000 trial, with AbPA measured at 4 time points (4, 8, 26, and 30 weeks post-baseline) in response to either 3 or 4 doses of AVA. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several lines of evidence have supported a host genetic contribution to vaccine response, but genome-wide assessments for specific determinants have been sparse. Here we describe a genome-wide association study (GWAS) of protective antigen-specific antibody (AbPA) responses among 726 European-Americans who received Anthrax Vaccine Adsorbed (AVA) as part of a clinical trial. After quality control, 736,996 SNPs were tested for association with the AbPA response to 3 or 4 AVA vaccinations given over a 6-month period. No SNP achieved the threshold of genome-wide significance (p=5 × 10(-8)), but suggestive associations (p<1 × 10(-5)) were observed for SNPs in or near the class II region of the major histocompatibility complex (MHC), in the promoter region of SPSB1, and adjacent to MEX3C. Multivariable regression modeling suggested that much of the association signal within the MHC corresponded to previously identified HLA DR-DQ haplotypes involving component HLA-DRB1 alleles of *15:01, *01:01, or *01:02. We estimated the proportion of additive genetic variance explained by common SNP variation for the AbPA response after the 6 month vaccination. This analysis indicated a significant, albeit imprecisely estimated, contribution of variation tagged by common polymorphisms (p=0.032). Future studies will be required to replicate these findings in European Americans and to further elucidate the host genetic factors underlying variable immune response to AVA.
    Full-text · Article · May 2012 · Vaccine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anthrax is a disease primarily of herbivorous animals, although all mammals including humans are also vulnerable when come in direct contact with infected animals. In country like India, cutaneous anthrax is a public health problem in several areas. Hence, a simple and efficacious serodiagnostic assay for large scale surveillance of endemic population is required. In the present study, we developed a field usable, qualitative enzyme linked immuno-sorbent assay (ELISA) for serodiagnosis of human anthrax. The results are observed on visual basis and no sophisticated instrument is required. Anti-PA IgG was determined by visual examination of ELISA results using a total of 225 serum samples (160 from healthy humans, 5 from PA vaccinated individuals and 60 from confirmed anthrax cases) from different human groups. Comparison of the ELISA results with the results obtained from OD values showed compatible sensitivity and specificity. The assay sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were found to be 100%. The developed assay can be a very useful tool for serological diagnosis of anthrax infection in human population.
    No preview · Article · Dec 2012 · Microbiology and Immunology
Show more